Results 211 to 220 of about 521,269 (357)
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong +9 more
wiley +1 more source
The CD97-PPM1G axis dampens antiviral immunity by dephosphorylating IRF7 in type I interferon pathway. [PDF]
Chang H +8 more
europepmc +1 more source
HSV-1 Targets Lymphatic Vessels in the Eye and Draining Lymph Node of Mice Leading to Edema in the Absence of a Functional Type I Interferon Response [PDF]
Katie M. Bryant-Hudson +5 more
openalex +1 more source
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li +6 more
wiley +1 more source
Correction: Type I Interferon: Potential Therapeutic Target for Psoriasis?
Yihong Yao +10 more
doaj +3 more sources
Correction: TRIM21 regulation of IRF-mediated type I interferon signaling in systemic autoimmune diseases. [PDF]
Panlu K +7 more
europepmc +1 more source
25 Stimulator of interferon genes (sting) plays a crucial role in type-i ifn production induced by the sera from sle patients [PDF]
Yasuhiro Kato +3 more
openalex +1 more source
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou +9 more
wiley +1 more source
Human ISG15 deficiency unveils impaired healing of ulcerations via type I interferon-mediated fibrosis. [PDF]
Sazeides C +19 more
europepmc +1 more source
Lysosome‐targeting chimeras (LYTACs) enable degradation of extracellular and membrane proteins via lysosomal trafficking. We report a novel IGF‐II mutant (Del1–7, Y27L) that selectively engages IGF‐IIR while avoiding IGF‐IR and IR‐A. mutIGF‐II–based LYTACs enhance target internalization and degradation and support a genetically encodable, all‐protein ...
Yuan Zhao +16 more
wiley +1 more source

